Craig A Tooman Form 3 Silence Therapeutics / CRAIG A TOOMAN ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

TOOMAN CRAIG A

(Last) (First) (Middle)

C/O SILENCE THERAPEUTICS PLC

72 HAMMERSMITH ROAD

(Street)

LONDON X0 W14 8TH

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2025

3. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President and CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	33,486	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Option (Right to Buy)	(1)	01/06/2031	Ordinary Shares	580,000	7.02	D
Employee Share Option (Right to Buy)	(2)	01/06/2032	Ordinary Shares	264,999	7.87	D
Employee Share Option (Right to Buy)	(3)	02/21/2032	Ordinary Shares	375,000	6.33	D
Employee Share Option (Right to Buy)	(4)	09/16/2032	Ordinary Shares	900,000	3.86	D
Employee Share Option (Right to Buy)	(5)	01/05/2033	Ordinary Shares	2,100,000	5.13	D
Employee Share Option (Right to Buy)	(6)	09/14/2033	Ordinary Shares	216,960	3.33	D
Employee Share Option (Right to Buy)	(7)	01/04/2034	Ordinary Shares	650,880	5.9	D

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award vested on January 6, 2022, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

2. This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

3. This option vested or shall vest in equal monthly installments over a four-year period measured from one month following February 21, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

4. This option vested or shall vest in equal monthly installments over a five-year period measured from one month following September 16, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

5. This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 5, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.

6. One fourth (1/4th) of the shares subject to the option vested on September 14, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.

7. One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.

	/s/ Rhonda Hellums, Attorney-in-Fact	01/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.